AR112303A1 - Método para el tratamiento de un efecto secundario de la inmunoterapia - Google Patents
Método para el tratamiento de un efecto secundario de la inmunoterapiaInfo
- Publication number
- AR112303A1 AR112303A1 ARP180101693A AR112303A1 AR 112303 A1 AR112303 A1 AR 112303A1 AR P180101693 A ARP180101693 A AR P180101693A AR 112303 A1 AR112303 A1 AR 112303A1
- Authority
- AR
- Argentina
- Prior art keywords
- mir
- msc
- immunotherapy
- mesenchymal
- side effect
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una célula madre mesenquimal (MSC) para su uso en el tratamiento de un efecto secundario de la inmunoterapia en un sujeto que ha sido sometido o está siendo sometido a inmunoterapia. Reivindicación 15: Una composición terapéutica para tratar, mejorar o reducir un efecto secundario de la inmunoterapia en un sujeto mamífero, en donde dicha composición terapéutica comprende una célula madre mesenquimal (MSC), en donde la MSC se obtiene mediante un método que comprende: (a) cultivar una célula de mesodermo primitiva en un medio para formación de una colonia de células mesenquimales (M-CFM) que contiene LiCl y FGF2, pero excluyendo PDGF, en condiciones normóxicas, durante el tiempo suficiente como para que se forme una colonia mesenquimal; y (b) cultivar la colonia mesenquimal de (a) en forma adherente, para producir la MSC, en donde la MSC de (b) expresa miR-145-5p, miR-181b-5p, y miR-214-3p, pero no miR-127-3p y miR-299-5p, y/o tiene fenotipo CD73⁺ CD105⁺ CD90⁺ CD146⁺ CD44⁺ CD10⁺ CD31⁻ CD45⁻. Reivindicación 16: Un recipiente que contiene una MSC que expresa miR-145-5p, miR-181b-5p, y miR-214-3p, pero no miR-127-3p y miR-299-5p, y/o tiene fenotipo CD73⁺ CD105⁺ CD90⁺ CD146⁺ CD44⁺ CD10⁺ CD31⁻ CD45⁻.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017902301A AU2017902301A0 (en) | 2017-06-16 | Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112303A1 true AR112303A1 (es) | 2019-10-16 |
Family
ID=64658783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101693 AR112303A1 (es) | 2017-06-16 | 2018-06-15 | Método para el tratamiento de un efecto secundario de la inmunoterapia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200323922A1 (es) |
| EP (1) | EP3638264A1 (es) |
| JP (1) | JP2020523400A (es) |
| AR (1) | AR112303A1 (es) |
| AU (1) | AU2018285953A1 (es) |
| BR (1) | BR112019026172A2 (es) |
| CA (1) | CA3066799A1 (es) |
| MX (1) | MX2019014867A (es) |
| RU (1) | RU2019143743A (es) |
| SG (1) | SG11201912200YA (es) |
| TW (1) | TW201920659A (es) |
| WO (1) | WO2018227244A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001909TA (en) | 2017-09-15 | 2020-04-29 | Cynata Therapeutics Ltd | Method for treating allergic airways disease (aad)/ asthma |
| WO2022176735A1 (ja) * | 2021-02-22 | 2022-08-25 | ロート製薬株式会社 | 糖尿病の予防及び／又は治療剤 |
| US20230277595A1 (en) * | 2021-02-22 | 2023-09-07 | Rohto Pharmaceutical Co., Ltd. | Prophylactic and/or therapeutic agent for diabetes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8932852B2 (en) * | 2009-08-14 | 2015-01-13 | Case Western Reserve University | Compositions and methods of treating inflammatory bowel disease |
| CN104471059B (zh) * | 2012-07-12 | 2018-04-17 | 珠海横琴爱姆斯坦生物科技有限公司 | 人胚胎干细胞衍生的间充质样干细胞、方法及其应用 |
| KR102151210B1 (ko) * | 2013-03-13 | 2020-09-02 | 위스콘신 얼럼나이 리서어치 화운데이션 | 규정된 조건하에서 인간 만능성 줄기 세포의 조혈내피세포 분화를 위한 방법 및 재료 |
| EP3182984B1 (en) * | 2014-08-18 | 2019-10-30 | Apceth GmbH & Co. KG | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
| CA3017772C (en) * | 2016-03-16 | 2023-02-21 | Cynata Therapeutics Limited | Colony forming medium and use thereof |
| CN108884440A (zh) * | 2016-04-01 | 2018-11-23 | 埃普塞斯有限责任两合公司 | 用于增强免疫疗法的抗肿瘤活性的间充质干细胞 |
-
2018
- 2018-06-13 JP JP2019569829A patent/JP2020523400A/ja active Pending
- 2018-06-13 AU AU2018285953A patent/AU2018285953A1/en not_active Abandoned
- 2018-06-13 EP EP18817555.8A patent/EP3638264A1/en not_active Withdrawn
- 2018-06-13 SG SG11201912200YA patent/SG11201912200YA/en unknown
- 2018-06-13 CA CA3066799A patent/CA3066799A1/en not_active Abandoned
- 2018-06-13 MX MX2019014867A patent/MX2019014867A/es unknown
- 2018-06-13 BR BR112019026172-9A patent/BR112019026172A2/pt not_active IP Right Cessation
- 2018-06-13 US US16/621,886 patent/US20200323922A1/en not_active Abandoned
- 2018-06-13 WO PCT/AU2018/050584 patent/WO2018227244A1/en active Application Filing
- 2018-06-13 RU RU2019143743A patent/RU2019143743A/ru not_active Application Discontinuation
- 2018-06-14 TW TW107120586A patent/TW201920659A/zh unknown
- 2018-06-15 AR ARP180101693 patent/AR112303A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201920659A (zh) | 2019-06-01 |
| WO2018227244A1 (en) | 2018-12-20 |
| RU2019143743A (ru) | 2021-07-16 |
| EP3638264A1 (en) | 2020-04-22 |
| BR112019026172A2 (pt) | 2020-06-30 |
| US20200323922A1 (en) | 2020-10-15 |
| AU2018285953A1 (en) | 2020-01-16 |
| SG11201912200YA (en) | 2020-01-30 |
| MX2019014867A (es) | 2020-02-13 |
| CA3066799A1 (en) | 2018-12-20 |
| JP2020523400A (ja) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180266T1 (hr) | Postupak priprave osnovnog medija za kulturu mezenhimnih matičnih stanica, osnovni medij za kulturu mezenhimnih matičnih stanica, te terapijsko sredstvo za stanice koje se uzgaja i diferencira uz njegovu upotrebu | |
| JP2016116523A5 (es) | ||
| AR112303A1 (es) | Método para el tratamiento de un efecto secundario de la inmunoterapia | |
| MX2018010828A (es) | Medio para formar colonias y uso de este. | |
| SA519401455B1 (ar) | طريقة لعزل الخلايا الجذعية اللحمية المتوسطية من الغشاء السلوي للحبل السري باستخدام مستنبت خلايا متوسطية | |
| Sowa et al. | Adipose stromal cells contain phenotypically distinct adipogenic progenitors derived from neural crest | |
| MX2018001531A (es) | Medio de cultivo celular complementado con taurina y metodos de uso. | |
| BR112015022770A8 (pt) | meio e sistema de cultivo da célula livre de xenógeno, livre de albumina, forma concentrada, métodos de diferenciação de células-tronco pluripotentes humanas, para a produção de mesenquimoangioblastos e sistema definido de cultivo da célula para diferenciação hematoendotelial das células- tronco pluripotentes humanas | |
| JP2015507921A5 (es) | ||
| CA2909230C (en) | Method for inducing alveolar epithelial progenitor cells | |
| Tantrawatpan et al. | Pluripotent gene expression in mesenchymal stem cells from human umbilical cord Wharton's jelly and their differentiation potential to neural-like cells. | |
| GB2548740A (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
| JP2010530214A5 (es) | ||
| PH12016502330B1 (en) | Method for preparing induced pluripotency stem cells from mesenchymal stem cells by using phlorotannin fraction | |
| SG10201903910RA (en) | Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same | |
| WO2012096461A3 (ko) | 줄기세포의 부유배양용 조성물 | |
| EA202190736A1 (ru) | Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью | |
| MX2017000142A (es) | Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. | |
| SA519402181B1 (ar) | عمليات لمعالجة خام الفوسفات | |
| WO2015064805A8 (ko) | 중간엽 줄기세포로부터 유도된 만능 줄기세포를 이용하여 연골세포로 분화시키는 방법 | |
| WO2012008733A3 (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
| EA201501002A1 (ru) | Способ культивирования гепатобластподобных клеток и продукт их культивирования | |
| Pham et al. | Fetal heart extract facilitates the differentiation of human umbilical cord blood-derived mesenchymal stem cells into heart muscle precursor cells | |
| EA201791233A1 (ru) | Материал стволовых клеток и способ его получения | |
| WO2012118349A3 (ko) | 제대혈 ｃｄ14 양성 단핵세포로부터 자연살해세포 분화 및 증식 방법 |